Pain Relief & Palliative Care, La Maddalena Cancer Center, Palermo, Italy.
Crit Rev Oncol Hematol. 2012 Sep;83(3):388-92. doi: 10.1016/j.critrevonc.2011.12.006. Epub 2012 Jan 25.
Malignant bowel obstruction (MBO) is a challenging complication of advanced cancer. Conservative treatment of inoperable MBO in terminal cancer patients has been found to be effective in controlling the distressing symptoms caused by this complication in inoperable cancer patients. Twenty years ago, octreotide was proposed to treat symptoms related to malignant bowel obstruction. Since then several reports have confirmed the efficacy of octreotide in the management of gastrointestinal symptoms of MBO. Fifteen randomized controlled trials or observational reports with a significant number of patients treated with octreotide have been reviewed; 281 patients were surveyed. Authors reported a therapeutic success ranging between 60% and 90%. Despite the limited number of controlled studies, the large experience acquired through 20 years suggests that octreotide is the first-choice antisecretory agent for MBO. As such, octreotide is the only drug approved by the health-care system in Italy for this treatment.
恶性肠梗阻（MBO）是晚期癌症的一种具有挑战性的并发症。对于终末期癌症患者中无法手术的 MBO，保守治疗已被证明可有效控制此类不可手术癌症患者的并发症引起的令人痛苦的症状。二十年前，奥曲肽被提议用于治疗与恶性肠梗阻相关的症状。此后，多项报告证实了奥曲肽在治疗 MBO 的胃肠道症状方面的疗效。已经回顾了 15 项随机对照试验或具有大量接受奥曲肽治疗的患者的观察性报告；对 281 名患者进行了调查。作者报告的治疗成功率在 60%至 90%之间。尽管对照研究的数量有限，但 20 年来积累的丰富经验表明，奥曲肽是 MBO 的首选抗分泌剂。因此，奥曲肽是意大利医疗保健系统批准用于该治疗的唯一药物。
